COMMUNIQUÉS West-GlobeNewswire

Immatics Announces Pricing of $150 Million Public Offering

11/10/2024 - 02:50

H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer [...]

Upstream Bio Announces Pricing of Upsized Initial Public Offering

11/10/2024 - 01:35

WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory [...]

StateHouse Announces Canadian Parent Enters Bankruptcy Proceedings in Canada following Initiation of Receivership Proceedings in the U.S.

11/10/2024 - 01:26

SAN DIEGO and TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, today [...]

CAMP4 Announces Pricing of Initial Public Offering

11/10/2024 - 01:07

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed [...]

Procaps Issues Shareholder Letter Update

10/10/2024 - 23:26

MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the [...]

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

10/10/2024 - 23:24

HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology [...]

AVITA Medical to Announce Third Quarter 2024 Financial Results

10/10/2024 - 23:15

VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

10/10/2024 - 23:12

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]

Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025

10/10/2024 - 23:03

Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience FRANKLIN, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clover Health [...]

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10/10/2024 - 22:40

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]

Procedure of the Annual General Meeting

10/10/2024 - 22:35

ANNOUNCEMENT NO. 277 10 October 2024 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 10 October 2024 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General [...]

Codexis to Report Third Quarter 2024 Financial Results on October 31

10/10/2024 - 22:05

REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report [...]

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024

10/10/2024 - 22:05

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, [...]

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

10/10/2024 - 22:05

Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 [...]

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

10/10/2024 - 22:05

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a [...]

Mercy Places First Commercial Eversense 365: The World’s First and Only 365-Day Continuous Glucose Monitor

10/10/2024 - 22:05

Senseonics’ Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia Diabetes Care [...]

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10/10/2024 - 22:05

Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical data has demonstrated greater anti-tumor activity [...]

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

10/10/2024 - 22:02

– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells – – Subcutaneous AK006 was well-tolerated with a favorable safety profile – – Top-line Phase 1 [...]

Appili Therapeutics – Press Release Correction

10/10/2024 - 21:40

HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili Therapeutics Announces [...]